Market Cap: $173.82B
Market Cap: $173.82B
Open
$49.46
Prev. Close
$41.60
High
$49.48
Low
$48.55
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America.
Novo Nordisk A/S trades on the New York Stock Exchange under the ticker NVO, priced in USD.
Novo Nordisk A/S has a market capitalisation of $173.82B, based on its latest share price.
NVO trades at 10.91 times its trailing 12-month earnings.
Over the past 52 weeks NVO has traded between $35.12 and $64.16.
Yes. Novo Nordisk A/S's dividend yields 4.20% at the current share price, paying out 46% of its earnings.
Highly profitable: keeps 33.9% of revenue as net profit.
The analyst consensus rating for NVO is Buy. Analysts' average 12-month price target of $46.44 implies 18% upside.
Maziar Mike Doustdar is the CEO of Novo Nordisk A/S, which is headquartered in Bagsvaerd.
Generated automatically from reported financial data. General information only, not financial advice.

Novo Nordisk A/S ( NVO ) is showcasing a promising turnaround as it navigates challenges in the competitive pharmaceutical landscape, particularly within the obesity and diabetes treatment sectors. Af…

Novo Nordisk A/S ( NVO ) stands at a crossroads as it seeks to navigate the complex and competitive landscape of the pharmaceutical industry. With its renowned GLP-1 medications, such as Wegovy and Oz…

Novo Nordisk A/S ( NVO ) is navigating a crucial phase in its journey as it contemplates its positioning in an increasingly competitive landscape. Once buoyed by the success of its GLP-1 medications,…

Novo Nordisk A/S ( NVO ) is navigating a pivotal point in its strategic trajectory as it embarks on a series of transformations to adapt to a changing market landscape. With increasing competition, pa…